The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78 - Roué, Gaël; Pérez-Galán, Patricia; Mozos, Ana; López-Guerra, Mónica; Xargay-Torrent, Sílvia; Rosich, Laia; Saborit-Villarroya, Ifigènia; Normant, Emmanuel; Campo, Elias; Colomer, Dolors (Blood, 2011)
Keywords: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Benzoquinones - pharmacology; Benzoquinones - therapeutic use; Biological and medical sciences; Boronic Acids - therapeutic use; Bortezomib; Cell Survival - drug effects; Cell Survival - genetics; Down-Regulation - drug effects; Drug Resistance, Neoplasm - drug effects; Drug Resistance, Neoplasm - genetics; Female; Gene Expression Regulation, Neoplastic - drug effects; Gene Knockdown Techniques; Heat-Shock Proteins - genetics; Heat-Shock Proteins - metabolism; Hematologic and hematopoietic diseases; HSP90 Heat-Shock Proteins - antagonists & inhibitors; Humans; Lactams, Macrocyclic - pharmacology; Lactams, Macrocyclic - therapeutic use; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma, Mantle-Cell - drug therapy; Lymphoma, Mantle-Cell - genetics; Male; Medical sciences; Mice; Mice, SCID; Mice, Transgenic; Middle Aged; Molecular Chaperones - genetics; Molecular Chaperones - metabolism; Pyrazines - therapeutic use; Receptors, Estrogen - metabolism; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Antineoplastic agent; Bortezomib; Hematology; Chaperone; B cell neoplasm; Malignant hemopathy; B-Lymphocyte; Non Hodgkin lymphoma; In vitro; Resistance; In vivo; Analog; Proteasome inhibitor; Lymphoproliferative syndrome; Mantle cell lymphoma; Heat shock protein; Dipeptides; Cancer; Heat shock protein 90